ECTS2013 Poster Presentations Osteoporosis: treatment (64 abstracts)
Patient preference and adherence to once-monthly oral minodronate in Japanese osteoporotic patients previously using daily or weekly bisphosphonates
Satoshi Ikeda 1 , Akinori Sakai 2 , Nobukazu Okimoto 3, , Kitau Teshima 4 , Shinobu Arita 5 , Hidehiro Matsumoto 6 , Hiroshi Tsurukami 7 , Yuichi Okazaki 8 , Masato Nagashima 9 , Fumio Fukuda 10 & Toru Yoshioka 11
1Ken-Ai Memorial Hospital, Onga, Fukuoka, Japan; 2University of Occupational and Environmental Health, Kitakyusyu, Fukuoka, Japan; 3Okimoto Clinic, Kure, Hiroshima, Japan; 4Teshima Orthopaedic Clinic, Kitakyusyu, Fukuoka, Japan; 5Obase Hospital, Miyako, Fukuoka, Japan; 6Sanzai Hospital, Miyazaki, Japan; 7Tsurukami Orthopaedic and Rheumatoid Clinic, Tamana, Fukuoka, Japan; 8Makiyama Central Hospital, Kitakyusyu, Fukuoka, Japan; 9Katsuki Neurosurgery and Orthopaedic Clinic, Nougata, Fukuoka, Japan; 10Kitakyushu General Hospital, Kitakyusyu, Fukuoka, Japan; 11Saka Midorii Hospital, Hiroshima, Japan; 12Okamoto Orthopaedics and Sports Clinic, Hiroshima, Japan.
Introduction: Bisphosphonates (BPs) are currently the mainstay of treatment in osteoporosis; however, the complex dosing regimens might interfere with long-term adherence, which provided the rationale to develop BPs with less-frequent dosing schedules. Minodronate (MIN 50 mg), a highly potent new-generation BP, is the first BP available as a once-monthly oral regimen in Japan. The aim of the present study was to investigate patient preference for, and adherence to, MIN 50 mg in Japanese osteoporotic patients previously using daily or weekly BPs.
Methods: We conducted a prospective multicenter study involving 11 institutions and 389 patients (367 females) in Japan. At enrollment, participants completed a self-administered questionnaire to see whether they were willing to switch to MIN 50 mg or continue taking their current BP. According to their preference, subjects were assigned to either MIN 50 mg or their current BP. Treatment adherence was monitored for 6 months, and patient satisfaction levels with the therapy were assessed at 6 months.
Results: Of the 389 patients using daily or weekly BPs, 258 patients (66.1%) were willing to switch to MIN 50 mg, mainly because they expect less-frequent dosing would be more convenient. Significantly more patients, who were dissatisfied with their current BP (e.g. insufficient efficacy) or who have ever missed taking any doses of their current BP, were more willing to switch to MIN 50 mg than continuing their current BP (P<0.01). Treatment adherence at 6 months was significantly higher in the MIN 50 mg-switched group compared with the previous BP-continued group (88.7 vs 78.7%, P<0.05). After 6 months, patients who switched and persisted with MIN 50 mg all preferred MIN 50 mg rather than their prior BP.
Conclusion: Once-monthly oral MIN 50 mg was associated with better medication adherence than daily or weekly dosing during a 6-month observation period. MIN 50 mg may provide patients with a more convenient treatment option and enhance compliance and long-term persistence with therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more